{
    "clinical_study": {
        "@rank": "26783", 
        "arm_group": {
            "arm_group_label": "EGFR+ Solid Tumor", 
            "arm_group_type": "Experimental", 
            "description": "EGFR+ Solid Tumor"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1, first-in-human  study to determine the recommended dose of IMGN289 in\n      adult patients with advanced EGFR-positive tumors."
        }, 
        "brief_title": "A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors", 
        "condition": "EGFR Positive Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years old at time of consent\n\n          -  Diagnosed with a solid tumor that has progressed despite standard therapy or     for\n             which no standard effective or curative options exist or are suitable\n\n          -  EGFR-positive tumor expression\n\n          -  Adequate blood and organ function\n\n          -  Must agree to use contraception while on study and for 12 weeks after the last dose\n             of IMGN289 as applicable\n\n          -  Must be willing and able to sign informed consent and follow the study schedule and\n             other protocol requirements\n\n        Exclusion Criteria:\n\n          -  Other anti-cancer treatment during the study\n\n          -  Symptomatic brain metastases\n\n          -  Other clinically significant disease as defined by the protocol\n\n          -  Chronic skin condition that requires prescribed oral or intravenous treatment\n\n          -  History of severe rash that required discontinuation of prior EGFR targeted therapy\n\n          -  Receiving therapeutic doses of warfarin or heparin for anti-coagulation\n\n          -  Known diagnosis of HIV or active viral hepatitis\n\n          -  Women who are pregnant or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963715", 
            "org_study_id": "IMGN0501"
        }, 
        "intervention": {
            "arm_group_label": "EGFR+ Solid Tumor", 
            "intervention_name": "IMGN289", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "IMGN289", 
            "Antibody Drug Conjugate", 
            "antibody", 
            "EGFR", 
            "NSCLC", 
            "SCCHN", 
            "Head and neck", 
            "Squamous cell carcinoma", 
            "Solid tumor", 
            "Immunogen", 
            "Lung", 
            "Phase 1"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "miranda.bryant@cshs.org", 
                    "last_name": "Miranda Bryant", 
                    "phone": "310-248-6735"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars-Sinai Medical Center"
                }, 
                "investigator": {
                    "last_name": "Alain C Mita, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "swest8@jhmi.edu", 
                    "last_name": "Sandra West"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
                }, 
                "investigator": {
                    "last_name": "Hyunseok Kang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rudo_makonzagoto@dfci.harvard.edu", 
                    "last_name": "Rudo Makonza-Goto", 
                    "phone": "617-632-6284"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Leena Gandhi, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wolfea@karmanos.org", 
                    "last_name": "Andrea Wolfe", 
                    "phone": "313-576-9365"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Patricia M LoRusso, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors", 
        "overall_contact": {
            "email": "imgn0501trial@immunogen.com", 
            "last_name": "Andrea Vergara-Silva, MD", 
            "phone": "781-895-0600"
        }, 
        "overall_official": {
            "affiliation": "ImmunoGen, Inc.", 
            "last_name": "Andrea Vergara-Silva, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with dose limiting toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Determine the amount of IMGN289 in participants blood (pharmacokinetics)", 
                "measure": "Area under the plasma concentration versus time curve", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Determine the amount of IMGN289 in participants blood (pharmacokinetics)", 
                "measure": "Peak plasma concentration (Cmax) of IMGN289", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Assess whether participants develop an immune response to IMGN289", 
                "measure": "Presence of Human Anti Human Antibody and Human Anti Drug Antibody", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Assess preliminary anti-tumor activity", 
                "measure": "Tumor measurements per RECIST 1:1", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "ImmunoGen, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ImmunoGen, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}